Access to anti-retroviral drugs, female in Guatemala

Guatemala: Access to anti-retroviral drugs, female was 73.0% in 2024. ◆ Volatile

Latest (2024)
73.0%
Change on year
down 6.4%
World rank
71st
of 141 countries
All-time high
78.0%
in 2023
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Guatemala, 2000–2024

0204060802000201220242000: 0 %2001: 0 %2002: 0 %2003: 3 %2004: 3 %2005: 6 %2006: 10 %2007: 18 %2008: 29 %2009: 34 %2010: 38 %2011: 52 %2012: 54 %2013: 63 %2014: 67 %2015: 63 %2016: 62 %2017: 65 %2018: 68 %2019: 70 %2020: 68 %2021: 70 %2022: 73 %2023: 78 %2024: 73 %

Source: UNAIDS estimates. Measured in %.

Analysis

Guatemala recorded 73.0% for access to anti-retroviral drugs, female in 2024.

That represents a change of down 6.4% on the previous year and up 9.0% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Guatemala peaked at 78.0% in 2023 and was at its lowest, 0.0%, in 2000.

Guatemala ranks 71st of 141 countries on this measure, in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Guatemala, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Guatemala, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 3.0%
2004 3.0% +0.0%
2005 6.0% +100.0%
2006 10.0% +66.7%
2007 18.0% +80.0%
2008 29.0% +61.1%
2009 34.0% +17.2%
2010 38.0% +11.8%
2011 52.0% +36.8%
2012 54.0% +3.8%
2013 63.0% +16.7%
2014 67.0% +6.3%
2015 63.0% -6.0%
2016 62.0% -1.6%
2017 65.0% +4.8%
2018 68.0% +4.6%
2019 70.0% +2.9%
2020 68.0% -2.9%
2021 70.0% +2.9%
2022 73.0% +4.3%
2023 78.0% +6.8%
2024 73.0% -6.4%

Averages by decade

DecadeAverage LowestHighest Years
2000s 10.3% 0.0% 34.0% 10
2010s 60.2% 38.0% 70.0% 10
2020s 72.4% 68.0% 78.0% 5

Countries ranked near Guatemala

  1. 69 Comoros 74.0% compare
  2. 69 El Salvador 74.0% compare
  3. 71 Bahrain 73.0% compare
  4. 71 Central African Republic 73.0% compare
  5. 71 Mali 73.0% compare
  6. 71 Sri Lanka 73.0% compare

See the full ranking of 160 places →

More gender data for Guatemala

All data for Guatemala →

Frequently asked questions

What is access to anti-retroviral drugs, female in Guatemala?
Access to anti-retroviral drugs, female in Guatemala was 73.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Guatemala?
The highest recorded value was 78.0% in 2023.
What is the lowest access to anti-retroviral drugs, female recorded in Guatemala?
The lowest recorded value was 0.0% in 2000.
How does Guatemala rank for access to anti-retroviral drugs, female?
Guatemala ranks 71st out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Guatemala?
Over the last ten years it is up 9.0%. The long-run trend across the full record is volatile.
Where does this Guatemala data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Guatemala. Statizoid, drawing on UNAIDS estimates. Retrieved 09 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/guatemala/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/guatemala/">Access to anti-retroviral drugs, female in Guatemala</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.